Expertise in
2
conditions

Tudor-eliade E. Ciuleanu

Institutul Oncologic Prof. Dr. Ion Chiricuta, 
Cluj-napoca, CJ, RO 
Expertise in
2
conditions
Institutul Oncologic Prof. Dr. Ion Chiricuta, 
Cluj-napoca, CJ, RO 

Overview

Tudor-eliade Ciuleanu practices practicing medicine in Cluj-napoca, Romania.

Ciuleanu is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Cystectomy.

They are actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 1 clinical trial.

Locations

Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-napoca, CJ, Romania
Other Locations
34-36 Gh. Bilascu St, Cluj-napoca, CJ 400015, Romania

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3

50 Total Publications

Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 08, 2026

Frequently Asked Questions about Tudor-eliade E. Ciuleanu

Is Tudor-eliade E. Ciuleanu a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Tudor-eliade E. Ciuleanu is classified as an Advanced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tudor-eliade E. Ciuleanu participate in research or clinical trials?

Yes. Tudor-eliade E. Ciuleanu has published 50 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Tudor-eliade E. Ciuleanu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ciuleanu's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile